Meeting
2020 ASCO Virtual Scientific Program
A phase I, first-in-human, open-label, dose‑escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP‑3654 administered daily for 28 days to patients with advanced solid tumors.
Authors
Ignacio Garrido-Laguna
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
Ignacio Garrido-Laguna , Patrick Michael Dillon , Stephen Patrick Anthony , Margit Janat-Amsbury , Nissa Ashenbramer , Steven L Warner , Lars Mouritsen , Mark L. Wade , Clifford Whatcott , David Bearss , Siqing Fu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3586)
DOI
10.1200/JCO.2020.38.15_suppl.3586
Abstract #
3586
Poster Bd #
316
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Trials in progress: A phase 1, open-label, pharmacokinetic, safety and tolerability study of PF-07265807 (selective TAM kinase inhibitor) alone or with sasanlimab in patients with advanced or metastatic solid tumors.
First Author: Jessica Dreger McDermott
Poster
2020 ASCO Virtual Scientific Program
A phase I, first-in-human, open-label, dose‑escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP‑1287 administered daily to patients with advanced solid tumors.
First Author: Ben George
Poster
2018 ASCO Annual Meeting
A phase 1a / 1b first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP‑0903, a potent inhibitor of AXL kinase, administered daily for 21 days to patients with advanced solid tumors.
First Author: John Sarantopoulos
Poster
2015 ASCO Annual Meeting
Effect of itraconazole and rifampin on the pharmacokinetics of olaparib tablet formulation in patients with advanced solid tumours: Phase I open-label studies.
First Author: Elizabeth R. Plummer